Updated Feb. 19, 2013 at 1:25 p.m.

Premium Lock GSK, partner Theravance target December for heart disease drug decision

Published: 2013-02-19 13:20:00
Updated: 2013-02-19 13:25:26

Print this blog post

GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) said Tuesday that the New Drug Application (NDA) for a  investigational combination medicine to treat patients with chronic obstructive pulmonary disease (COPD) has been accepted by the U.S. Food and Drug Administration....

Read More
Read More

WRAL Tech Wire any time: Twitter, Facebook

Copyright 2014 WRAL Tech Wire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners


Vivek Wadhwa
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy